The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results.
 
Daniel M. Halperin
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Chimeric Therapeutics; Curium Pharma; Ipsen; Isotopen Technologien; Lexicon; Novartis; Radiomedix
Research Funding - Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Incyte (Inst); Tarveda Therapeutics (Inst); Tersera (Inst); Thermo Fisher Scientific (Inst)
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Amgen (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PMV Pharma (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Jennifer A. Chan
Stock and Other Ownership Interests - Merck
Honoraria - Advanced Accelerator Applications; Ipsen; Lexicon
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer (I); Crinetics Pharmaceuticals; Lexicon; Pfizer (I)
Research Funding - Lilly (Inst); Sanofi (Inst)
 
Lowell L. Hart
Honoraria - AstraZeneca; Daiichi Sankyo; G1 Therapeutics; Karyopharm Therapeutics; Novartis; Seagen; Veracyte
Consulting or Advisory Role - Amgen; G1 Therapeutics; Genentech/Roche; Merck; Seagen
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Genentech; Lilly; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Novartis (Inst); Seagen (Inst)
 
Natalie Cook
Honoraria - Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); UCB (Inst)
 
Vipul M. Patel
No Relationships to Disclose
 
Benjamin L. Schlechter
Honoraria - Quercegen Pharmaceuticals
 
Judith Cave
Travel, Accommodations, Expenses - Amgen; Roche
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; AstraZeneca; Bayer; Bristol-Myers Squibb; G1 Therapeutics; Ipsen; Seagen; Takeda
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Seagen (Inst); Symphogen (Inst); Takeda (Inst); Tesaro (Inst); United Therapeutics (Inst)
 
Lawrence Scott Blaszkowsky
Stock and Other Ownership Interests - Pfizer (I)
 
Tim Meyer
Consulting or Advisory Role - Beigene; Bristol-Myers Squibb; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Jennifer Rachel Eads
Employment - Bristol-Myers Squibb (I)
Honoraria - Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; lexicon
Research Funding - Incyte; MedImmune (Inst); Tarveda Therapeutics (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I)
 
Daniel Culp
Employment - Tarveda Therapeutics
 
Kristina Kriksciukaite
Employment - Tarveda Therapeutics
 
Laura Mei
Employment - Tarveda Therapeutics
Stock and Other Ownership Interests - Alexion Pharmaceuticals; Tarveda Therapeutics
 
Mark Bilodeau
Employment - Tarveda Therapeutics
Leadership - Tarveda Therapeutics
Stock and Other Ownership Interests - Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Inventor on Tarveda Therapeutics IP
 
Jeffrey Bloss
Employment - Tarveda Therapeutics
Leadership - Tarveda Therapeutics
 
Matthew H. Kulke
Research Funding - Bristol Myers Squibb (Inst); tersera (Inst)